Clinical Trial Update: A Phase 3 Clinical Study of QL2106 Injection [Phase 3]

View source ↗

Summary

A Phase 3 clinical study of QL2106 Injection for plaque psoriasis is listed as not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• QL2106 Injection (QL2106)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Plaque Psoriasis | Phase 3 | Status: NOT_YET_RECRUITING